Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded rapid dissolve tablet containing tadalafil, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing tadalafil are listed in tablet and suspension forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, manufactured as oral tablets and an oral suspension, that compounding pharmacies prepare in oral solid, dissolving and liquid dosage forms.
Tadalafil belongs to the phosphodiesterase type 5 (PDE5) inhibitor class. In plain terms, the body uses a messenger molecule called cGMP to relax smooth muscle in blood vessels; PDE5 breaks cGMP down, and tadalafil slows that breakdown so the messenger lasts longer. The manufactured tablet Cialis is FDA-approved for erectile dysfunction, for the signs and symptoms of benign prostatic hyperplasia, and for both together. The same molecule, sold as Adcirca, is approved to improve exercise ability in pulmonary arterial hypertension, and an FDA-approved tadalafil oral suspension (Tadliq) is also manufactured. Prescribers may order it compounded when they want a strength that is not manufactured, a dissolving form, a liquid in a strength or flavor that is not manufactured, a preparation without a specific excipient, or a combination with another ingredient. Compounded tadalafil is not FDA-approved and requires a prescription.
The manufactured tablet has no boxed warning. Never combine tadalafil with nitrates, including nitroglycerin and isosorbide, or with guanylate cyclase stimulators such as riociguat; the combination can cause a dangerous drop in blood pressure. The label advises against use after a recent heart attack or stroke, with unstable angina, uncontrolled blood pressure or rhythm problems, or severe liver disease, and calls for caution with alpha blockers, other blood pressure medicines and heavy alcohol. CYP3A4 inhibitors such as ketoconazole and ritonavir raise tadalafil levels, inducers such as rifampin lower them, and MedlinePlus flags grapefruit and St. John's wort. Sudden vision loss, sudden hearing loss, or an erection lasting more than four hours needs immediate care. Common side effects are headache, indigestion, back pain, muscle aches and flushing. Cialis is not indicated for women; LactMed reports no breastfeeding data. If side effects are severe or persist, talk to your prescriber or pharmacist.
Tadalafil is a selective PDE5 inhibitor. Sexual stimulation releases nitric oxide, raising cGMP in corpus cavernosum smooth muscle; tadalafil prolongs the cGMP signal by blocking its hydrolysis, and its action depends on sexual stimulation. It is highly selective for PDE5 over other phosphodiesterases except PDE11, and its low PDE6 activity is associated with a lower rate of visual disturbance than other agents in the class. Orally, time to peak is about 2 hours, bioavailability about 80 percent, half-life about 17.5 hours in healthy men and longer in older men, absorption unaffected by food, metabolism mainly via CYP3A4, and excretion roughly two thirds fecal and one third urinary; steady state is reached in about 5 days with daily dosing. Cialis is labeled for erectile dysfunction, benign prostatic hyperplasia, and both; Adcirca is labeled for pulmonary arterial hypertension. A compounded tadalafil oral liquid formulation has been published in the International Journal of Pharmaceutical Compounding. Dosing frequency and CYP3A4-related adjustments per prescriber. Monitoring per label: cardiovascular fitness for sexual activity, blood pressure when combined with alpha blockers or antihypertensives, renal and hepatic function for dose selection. Not a controlled substance.
Wash and dry your hands first. Place the tablet on or under your tongue, or between your cheek and gum if your label says so, and let it dissolve. Do not chew or swallow it whole unless directed. Dissolving usually takes up to a minute. Follow your label for timing around food and drink.
These tablets are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Keep them in the closed container at room temperature, away from moisture and heat, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 tablet under the tongue and let dissolve before swallowing. Do not chew.
